A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.

Backed by influencial names in the life sciences industry, Latent Labs offers an AI platform to accelerate and improve drug ...

The company has assembled a team that hails from DeepMind and Microsoft, AI in drug discovery specialist Exscientia, genomics and machine learning company Zymergen (bought by Ginkgo Bioworks in 2022), ...

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for drug discovery and development ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

Latent Labs, the company building AI foundation models to make biology programmable, today emerged from stealth with $50M in total funding to accelerate their progress and partnerships.

Former DeepMind employees raise $40 million to launch London-based startup 'laser-focused' on AI protein design.